Analysis shows PD-1/PD-L1 pathway involvement in acute cellular rejection, suggesting therapeutic targets for heart transplant recipients.
The PD-1/PD-L1 pathway is involved in ACR regulation in human cardiac allografts. Increased PD-L1 expression during ACR may represent a counteractive mechanism to limit alloimmune-mediated tissue injury, supporting PD-1/PD-L1 as a potential therapeutic target in heart TPL recipients.
No takes yet. Share an insight, caveat, or question.
Yim et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: